American biotech firm Biogen (BIIB), whose shares fell nearly 16.5% this year, saw it further dip 2.4% to $259.30 in pre-market trade, despite the strong first-quarter earnings.
Earnings, excluding items, jumped to $6.05 per share this quarter from last year’s $5.20 per share. On a diluted basis, Biogen reported earnings of $5.54 per share, marking a modest improvement from $3.46 per share during the same quarter last year.
Weeks back, Biogen along with its South Korean partner Samsung Bioepis put an end to the long-running fight with AbbVie, over the biosimilar version of the latter’s key drug Humira. Based on the new deal, the partners will sell the copy-cat version of Humira — Imraldi — in Europe. This is expected to strengthen the firm’s biosimilar portfolio and even drive the revenue growth.
Revenue during the quarter jumped 11% to $3.1 billion, propelled by SPINRAZA (to treat spinal muscular atrophy), which contributed $364 million in global revenues, and biosimilars that contributed $128 million.
The company, with its wide range of products, leads the multiple-sclerosis market. During the quarter, Tecfidera — the top-selling multiple-sclerosis drug — generated revenues of about $987 million during the quarter. But since this space is getting crowded at a faster pace, the biotech firm is diversifying its portfolio.
The company is focusing on building its neuroscience pipeline. Hence, it paid $1 billion to expand its partnership with Ionis Pharma (IONS) to develop new antisense drugs to treat a wide of neurological disorders. During the quarter, the company even completed the transaction — of approx. $600 million — to acquire an experimental drug from pharma giant Pfizer that is developed to treat Schizophrenia.
“As pioneers in neuroscience, we continued to advance and expand our portfolio of potential breakthrough treatments for areas of high unmet need. We have added a new Phase 2 asset in our emerging growth area of neuropsychiatry, and we meaningfully enhanced our collaboration with Ionis to develop a new pipeline of gene- based therapies for neurological diseases,” said Michel Vounatsos, Biogen’s Chief Executive Officer.
PayPal Holdings Inc. (NASDAQ: PYPL) reported stronger-than-expected earnings and revenues for the first quarter of 2021. Shares of the payment service provider gained during Wednesday’s extended trading session soon after
Twilio (NYSE: TWLO) reported first quarter 2021 earnings results today. Revenue increased 62% year-over-year to $590 million. GAAP net loss widened to $206 million, or $1.24 per share, compared to
Uber Technologies (NYSE: UBER) reported first-quarter 2021 financial results after the regular market hours on Wednesday. The ride-hailing company reported Q1 revenue excluding the UK accrual of $3.5 billion, up